Heart Valve Devices – Market Insights – United States

The US heart valve device market continues to be driven by the introduction of novel products and key approvals for new indications of existing products. In particular, recent approvals of transcatheter tricuspid and mitral therapies, as well as the indication expansion of TAVI devices to treat asymptomatic, severe aortic stenosis patients, will support the market in coming years.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for heart valve devices in the US from 2019 through 2034.

Clinical trial results play an important role in the heart valve device market.

Which key players have secured first-mover advantages by securing approvals through positive clinical trial results?

Which novel devices have been approved or have failed to gain approval due to data from clinical trials?

How have recent clinical trial results impacted confidence in particular device types, and how will this affect procedure trends?

Securing approval for additional indications and CMS reimbursement are key strategies in the THV device market.

Which segments are being driven by the approval of new indications?

Which competitors are capitalizing on approvals for additional indications to gain a competitive advantage?

Which newly approved THV devices have received CMS reimbursement schemes recently?

The competitive landscape for the THV device market is evolving.

How are market dynamics changing following recent device approvals?

Which companies are expected to earn FDA approval for THV devices in upcoming years?